A Raythera Inc. patent describes tyrosine-protein kinase JAK2 (V617F mutant) inhibitors or degraders reported to be useful for the treatment of cancer.

Raythera Inc. has identified TNF-α modulators reported to be useful for the treatment of inflammatory disorders, autoimmune disease, neurological disorders, pain, cardiovascular disorders, cancer, metabolic disorders and eye disorders.